title: Regulation of fatty acid oxidation in mouse cumulus-oocyte complexes during maturation and modulation by PPAR agonists.
abstract: Fatty acid oxidation is an important energy source for the oocyte; however, little is known about how this metabolic pathway is regulated in cumulus-oocyte complexes. Analysis of genes involved in fatty acid oxidation showed that many are regulated by the luteinizing hormone surge during in vivo maturation, including acyl-CoA synthetases, carnitine transporters, acyl-CoA dehydrogenases and acetyl-CoA transferase, but that many are dysregulated when cumulus-oocyte complexes are matured under in vitro maturation conditions using follicle stimulating hormone and epidermal growth factor. Fatty acid oxidation, measured as production of ³H₂O from [³H]palmitic acid, occurs in mouse cumulus-oocyte complexes in response to the luteinizing hormone surge but is significantly reduced in cumulus-oocyte complexes matured in vitro. Thus we sought to determine whether fatty acid oxidation in cumulus-oocyte complexes could be modulated during in vitro maturation by lipid metabolism regulators, namely peroxisome proliferator activated receptor (PPAR) agonists bezafibrate and rosiglitazone. Bezafibrate showed no effect with increasing dose, while rosiglitazone dose dependently inhibited fatty acid oxidation in cumulus-oocyte complexes during in vitro maturation. To determine the impact of rosiglitazone on oocyte developmental competence, cumulus-oocyte complexes were treated with rosiglitazone during in vitro maturation and gene expression, oocyte mitochondrial activity and embryo development following in vitro fertilization were assessed. Rosiglitazone restored Acsl1, Cpt1b and Acaa2 levels in cumulus-oocyte complexes and increased oocyte mitochondrial membrane potential yet resulted in significantly fewer embryos reaching the morula and hatching blastocyst stages. Thus fatty acid oxidation is increased in cumulus-oocyte complexes matured in vivo and deficient during in vitro maturation, a known model of poor oocyte quality. That rosiglitazone further decreased fatty acid oxidation during in vitro maturation and resulted in poor embryo development points to the developmental importance of fatty acid oxidation and the need for it to be optimized during in vitro maturation to improve this reproductive technology.
authors: School of Paediatrics and Reproductive Health, The Robinson Institute, The University of Adelaide, Adelaide, South Australia, Australia.
authors: Kylie R
authors: KR
authors: Dunning
authors: School of Paediatrics and Reproductive Health, The Robinson Institute, The University of Adelaide, Adelaide, South Australia, Australia.
authors: Marie R
authors: MR
authors: Anastasi
authors: School of Paediatrics and Reproductive Health, The Robinson Institute, The University of Adelaide, Adelaide, South Australia, Australia.
authors: Voueleng J
authors: VJ
authors: Zhang
authors: School of Paediatrics and Reproductive Health, The Robinson Institute, The University of Adelaide, Adelaide, South Australia, Australia.
authors: Darryl L
authors: DL
authors: Russell
authors: School of Paediatrics and Reproductive Health, The Robinson Institute, The University of Adelaide, Adelaide, South Australia, Australia.
authors: Rebecca L
authors: RL
authors: Robker
mesh_terms: D000818:Animals; D001629:Bezafibrate / Q000494:pharmacology*; D054885:Cumulus Cells / Q000166:cytology / Q000378:metabolism*; D004815:Epidermal Growth Factor / Q000494:pharmacology; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D006728:Hormones / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D050356:Lipid Metabolism / Q000187:drug effects*; D008808:Mice, Inbred CBA; D009865:Oocytes / Q000166:cytology / Q000378:metabolism*; D010084:Oxidation-Reduction / Q000187:drug effects; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000378:metabolism; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*
chemical_list: D005227:Fatty Acids; D006728:Hormones; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D047492:Peroxisome Proliferator-Activated Receptors; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D004815:Epidermal Growth Factor; D005640:Follicle Stimulating Hormone; D001629:Bezafibrate